MARKET

SABS

SABS

SAB BIOTHERAPEUTICS INC
NASDAQ
3.850
+0.020
+0.52%
After Hours: 3.780 -0.07 -1.82% 19:07 03/27 EDT
OPEN
3.790
PREV CLOSE
3.830
HIGH
3.930
LOW
3.770
VOLUME
808.55K
TURNOVER
--
52 WEEK HIGH
6.60
52 WEEK LOW
1.000
MARKET CAP
270.56M
P/E (TTM)
55.40
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SABS last week (0316-0320)?
Weekly Report · 6d ago
SAB Biotherapeutics closes USD 85 million follow-on stock offering
Reuters · 03/19 20:08
Press Release: SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
Dow Jones · 03/19 20:01
SAB Biotherapeutics Launches Major Equity Financing Offering
TipRanks · 03/19 10:30
BUZZ-U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies
Reuters · 03/18 15:47
BUZZ-U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist
Reuters · 03/18 13:11
BUZZ-U.S. STOCKS ON THE MOVE-Lululemon, Swarmer, DocuSign
Reuters · 03/18 11:39
BUZZ-SAB Biotherapeutics slips on $85 mln equity offering
Reuters · 03/18 10:57
More
About SABS
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.

Webull offers SAB Biotherapeutics Inc stock information, including NASDAQ: SABS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SABS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SABS stock methods without spending real money on the virtual paper trading platform.